Pereira P, Fernandes B, Dos Santos V, Cabral W, Lovo-Martins M, Alonso L
Pathogens. 2023; 12(8).
PMID: 37623972
PMC: 10457850.
DOI: 10.3390/pathogens12081012.
Rice A, Long Y, King S
Biomolecules. 2021; 11(2).
PMID: 33673069
PMC: 7918234.
DOI: 10.3390/biom11020267.
Paiva C, Medei E, Bozza M
PLoS Pathog. 2018; 14(4):e1006928.
PMID: 29672619
PMC: 5908069.
DOI: 10.1371/journal.ppat.1006928.
Garavaglia P, Laverriere M, Cannata J, Garcia G
Antimicrob Agents Chemother. 2016; 60(5):2664-70.
PMID: 26856844
PMC: 4862456.
DOI: 10.1128/AAC.02185-15.
Santos E, Novaes R, Cupertino M, Bastos D, Klein R, Silva E
Antimicrob Agents Chemother. 2015; 59(10):5999-6006.
PMID: 26169419
PMC: 4576071.
DOI: 10.1128/AAC.00779-15.
Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.
Marson M, Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Mastrantonio G
Eur J Drug Metab Pharmacokinet. 2014; 40(2):209-17.
PMID: 24711214
DOI: 10.1007/s13318-014-0195-8.
Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population.
Mejia A, Hall B, Taylor M, Gomez-Palacio A, Wilkinson S, Triana-Chavez O
J Infect Dis. 2012; 206(2):220-8.
PMID: 22551809
PMC: 3379838.
DOI: 10.1093/infdis/jis331.
Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation.
Hall B, Wilkinson S
Antimicrob Agents Chemother. 2011; 56(1):115-23.
PMID: 22037852
PMC: 3256028.
DOI: 10.1128/AAC.05135-11.
Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.
Garcia-Bournissen F, Altcheh J, Giglio N, Mastrantonio G, Della Vedova C, Koren G
Paediatr Drugs. 2009; 11(1):33-7.
PMID: 19127950
DOI: 10.2165/0148581-200911010-00012.
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
Faundez M, Lopez-Munoz R, Torres G, Morello A, Ferreira J, Kemmerling U
Antimicrob Agents Chemother. 2008; 52(5):1837-9.
PMID: 18332173
PMC: 2346639.
DOI: 10.1128/AAC.01454-07.
Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages.
Revelli S, Le Page C, Piaggio E, Wietzerbin J, Bottasso O
Clin Exp Immunol. 1999; 118(2):271-7.
PMID: 10540190
PMC: 1905429.
DOI: 10.1046/j.1365-2249.1999.01053.x.
Effect of tingenone, a quinonoid triterpene, on growth and macromolecule biosynthesis in Trypanosoma cruzi.
Goijman S, Turrens J, Marini-Bettolo G, Stoppani A
Experientia. 1985; 41(5):646-8.
PMID: 3888660
DOI: 10.1007/BF02007701.
Some reactions and properties of nitro radical-anions important in biology and medicine.
Wardman P
Environ Health Perspect. 1985; 64:309-20.
PMID: 3830700
PMC: 1568617.
DOI: 10.1289/ehp.8564309.
Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi.
Diaz de Toranzo E, Castro J, Franke De Cazzulo B, Cazzulo J
Experientia. 1988; 44(10):880-1.
PMID: 3053234
DOI: 10.1007/BF01941187.
Redox cycling of radical anion metabolites of toxic chemicals and drugs and the Marcus theory of electron transfer.
Mason R
Environ Health Perspect. 1990; 87:237-43.
PMID: 2176587
PMC: 1567813.
DOI: 10.1289/ehp.9087237.
